Breast, prostatic and pancreatic cancers alter the zinc (Zn) metabolism. Mixed analyses of urinary Zn concentrations ([Zn]) and Zn secure isotope compositions (δ66Zn) might present a non-invasive method for tracing malignancy-induced Zn dyshomeostasis. On this research, we measured [Zn] and δ66Zn in urine from prostate (n = 22), breast (n = 16) and from ladies with benign breast illness (n = 14) and in contrast these to age-matched wholesome controls and revealed knowledge for pancreatic most cancers (n = 17). Our outcomes present most cancers-induced modifications are mirrored in greater urinary [Zn] and decrease urinary δ66Zn for pancreatic and prostate most cancers and benign breast illness when in comparison with wholesome controls.
For prostate most cancers, low [Zn] and excessive δ66Zn for sufferers of low-risk illness progresses in direction of excessive [Zn] and low δ66Zn for the higher-risk sufferers, demonstrates that [Zn] and δ66Zn in urine might function a dependable prognostic device. Urinary excretion of isotopically mild Zn by sufferers with prostatic and pancreatic most cancers might be the results of elevated reactive oxygen species in most cancersous cells, which limits the scavenging of hydroxyl radicals and thus facilitates the oxidation of metalloproteins with sulfur-rich ligands.
Urine from malignant breast most cancers sufferers reveals undistinguishable δ66Zn to wholesome controls, implying that the expression of metalloproteins with sulfur-rich ligands is stronger in breast most cancers tissues. In conclusion, urinary δ66Zn might present a non-invasive diagnostic device for pancreatic most cancers and help illness prognosis for prostate most cancers. These findings ought to translate to complete transverse and longitudinal cohort research in future.
Pancreatic strong pseudopapillary neoplasms (SPNs) are uncommon borderline tumours primarily affecting younger feminine sufferers. The variety of sufferers recognized with SPNs has elevated considerably within the final a long time owing to the elevated use of cross-sectional imaging investigating totally different stomach signs, while a major proportion are by the way found through the means of evaluating different pathologies. We herein current our institutional expertise of sufferers with SPN who underwent healing resection specializing in scientific, pathological options, and the long-term outcomes.
Throughout the inclusion interval, a complete of 19 sufferers had a pathological analysis of SPNs after surgical resection. Sixteen of them have been feminine (84%), whereas the median affected person age was 30 (vary 16-66) years. 9 sufferers (47%) underwent distal pancreatectomy and splenectomy, 2 (11%) underwent spleen preserving distal pancreatectomy, 6 (32%) underwent pancreatoduodenectomy, one (5%) underwent whole pancreatectomy, and one (5%) central pancreatectomy. Seventeen sufferers underwent R0 resection. Throughout a median follow-up of 23 months, no tumour recurrence or dying was recorded.
Supramolecular Nanofibrils Fashioned by Coassembly of Clinically Accepted Medicine for Tumor Photothermal Immunotherapy
Pancreatic most cancers, one of the deadly malignancies, compromises the efficiency of conventional therapeutic regimens within the clinic due to stromal resistance to systemic drug supply and poor prognosis brought on by tumor metastasis. Due to this fact, a biocompatible therapeutic paradigm that may successfully inhibit pancreatic tumor development whereas concurrently eliminating tumor metastasis is urgently wanted. Herein, supramolecular nanofibrils are fabricated by means of coassembly of clinically authorised immunomodulatory thymopentin and near-infrared indocyanine inexperienced for localized photothermal immunotherapy of pancreatic tumors.
The ensuing long-range ordered fibrous nanodrugs present improved photophysical capabilities for fluorescence imaging and photothermal conversion and considerably promote the proliferation and differentiation of antitumor immune cells. Therefore, the combination of fast photothermal remedy and reasonable immunomodulation for inhibiting tumor development and eliminating tumor metastasis is promising. The utilization of clinically authorised molecules to assemble nanodrugs administered by way of localized injection amplifies the complementary photothermal immunotherapeutic results of the elements, creating alternatives for scientific translation as a therapy for pancreatic most cancers.
The somatic mutation knowledge, transcriptome profiles and scientific data have been downloaded from the Most cancers Genome Atlas database. Gene expression distinction, Gene ontology, KEGG, gene set enrichment analyses and “CIBERSORT” algorithm have been carried out to display screen differentially expressed genes, enriched capabilities or pathways and immune infiltrates variations between excessive and low TMB teams. Single pattern gene set enrichment and unsupervised consensus clustering analyses have been used for immunity grouping. Immune cell infiltration and expressions of HLA and checkpoint genes have been investigated.
Stearoyl-CoA Desaturase 1 Potentiates Hypoxic plus Nutrient-Disadvantaged Pancreatic Most cancers Cell Ferroptosis Resistance
Hypoxia and nutrient hunger (H/NS) microenvironment, a notable attribute of pancreatic carcinoma, performs a important function in cell dying resistance and tumor recurrence. Nevertheless, its function in ferroptosis stays to be categorised. Right here, we discovered that H/NS contributed to the pancreatic most cancers cell ferroptosis resistance relying on the altered intracellular lipid compositions. Mechanistically, H/NS induced the upregulation of stearoyl-CoA desaturase 1 (SCD1), which promoted monounsaturated fatty acids (MUFAs) synthesis and guarded in opposition to lipid peroxidation.
Surprisingly, SCD1 confirmed a powerful correlation with antiferroptosis gene expression. Furthermore, short-hairpin RNA-based knockdown of SCD1 enhanced erastin-induced ferroptosis in vitro underneath H/NS. Lastly, our outcomes display the synergistic impact of erastin and A939572, a particular SCD1 inhibitor, in dictating pancreatic carcinoma subcutaneous ferroptotic dying. Taken collectively, our findings reveal a brand new function of the H/NS microenvironment in opposition to ferroptosis and recommend a possible therapeutic technique for overcoming ferroptosis resistance in pancreatic most cancers cells.
 CancerSeq™-Paraffin-Tissue-Tumor-Block:-Skin-Melanoma |
|
T2235218A-SB |
Biochain |
1 Block |
EUR 3097.85 |
 CancerSeq™-Plus-Paraffin-Tissue-Tumor-Sections:-Breast |
|
T2235086-SC |
Biochain |
5 curls |
EUR 600.95 |
 CancerSeq™-Paraffin-Tissue-Tumor-Slides:-Skin-Melanoma |
|
T2235218A-ST |
Biochain |
5 Slides |
EUR 441.7 |
 CancerSeq™-Plus-Paraffin-Tissue-Tumor-Sections:-Stomach |
|
T2235248-SC |
Biochain |
5 curls |
EUR 600.95 |
 CancerSeq™-Plus-Paraffin-Tissue-Tumor-Sections:-Thyroid |
|
T2235265-SC |
Biochain |
5 curls |
EUR 600.95 |
) Cancers/tumors of 40 types, 102 cases (1.5mm) |
|
MTU1021 |
Pantomics |
1 |
EUR 300 |
|
Description: 40 types of tumors, non-overlapping with MTU951, covering all the common benign, malignant and metastatic entities originated from 27 anatomic sites. Most of them have duplicates or triplicates from different individuals with corresponding uninvolved tissues as controls along with grading and TNM staging data. |
) SNCG (breast cancer-specific protein 1) |
|
Mab-606071 |
Antagene |
0.1mg |
EUR 240 |
 Antibody) Mutated In Colorectal Cancers (MCC) Antibody |
|
abx029386-400l |
Abbexa |
400 µl |
EUR 518.75 |
Mutated In Colorectal Cancers (MCC) Antibody |
|
abx029386-400ul |
Abbexa |
400 ul |
EUR 627.6 |
|
|
Mutated In Colorectal Cancers (MCC) Antibody |
|
abx029386-80l |
Abbexa |
80 µl |
EUR 250 |
|
|
Mutated In Colorectal Cancers (MCC) Antibody |
|
20-abx123165 |
Abbexa |
-
Ask for price
-
Ask for price
-
Ask for price
|
|
|
|
Mutated In Colorectal Cancers (MCC) Antibody |
|
abx113896-100l |
Abbexa |
100 µl |
EUR 612.5 |
Mutated In Colorectal Cancers (MCC) Antibody |
|
20-abx113896 |
Abbexa |
-
Ask for price
-
Ask for price
|
|
|
|
Mutated In Colorectal Cancers (MCC) Antibody |
|
abx210997-100l |
Abbexa |
100 µl |
EUR 350 |
Mutated In Colorectal Cancers (MCC) Antibody |
|
20-abx210997 |
Abbexa |
-
Ask for price
-
Ask for price
|
|
|
|
Mutated In Colorectal Cancers (MCC) Antibody |
|
abx210997-50l |
Abbexa |
50 µl |
EUR 250 |
Mutated In Colorectal Cancers (MCC) Antibody |
|
abx210998-100l |
Abbexa |
100 µl |
EUR 350 |
Mutated In Colorectal Cancers (MCC) Antibody |
|
20-abx210998 |
Abbexa |
-
Ask for price
-
Ask for price
|
|
|
|
Mutated In Colorectal Cancers (MCC) Antibody |
|
abx210998-50l |
Abbexa |
50 µl |
EUR 250 |
Mutated In Colorectal Cancers (MCC) Antibody |
|
abx235046-100g |
Abbexa |
100 µg |
EUR 350 |
Mutated In Colorectal Cancers (MCC) Antibody |
|
abx235046-100ug |
Abbexa |
100 ug |
EUR 661.2 |
|
|
 Mouse mAb) SNCG (Breast Cancer-Specific Protein 1) Mouse mAb |
|
MBS8538314-01mL |
MyBiosource |
0.1mL |
EUR 305 |
SNCG (Breast Cancer-Specific Protein 1) Mouse mAb |
|
MBS8538314-01mLAF405L |
MyBiosource |
0.1mL(AF405L) |
EUR 565 |
SNCG (Breast Cancer-Specific Protein 1) Mouse mAb |
|
MBS8538314-01mLAF405S |
MyBiosource |
0.1mL(AF405S) |
EUR 565 |
SNCG (Breast Cancer-Specific Protein 1) Mouse mAb |
|
MBS8538314-01mLAF610 |
MyBiosource |
0.1mL(AF610) |
EUR 565 |
SNCG (Breast Cancer-Specific Protein 1) Mouse mAb |
|
MBS8538314-01mLAF635 |
MyBiosource |
0.1mL(AF635) |
EUR 565 |
 Antibody) SNCG (breast cancer-specific protein 1) Antibody |
|
BF0110 |
Affbiotech |
200ul |
EUR 540 |
SNCG (breast cancer-specific protein 1) Antibody |
|
BF0110-100ul |
Affinity Biosciences |
100ul |
EUR 210 |
|
Description: WB,IHC,ELISA |
SNCG (breast cancer-specific protein 1) Antibody |
|
BF0110-200ul |
Affinity Biosciences |
200ul |
Ask for price |
|
Description: WB,IHC,ELISA |
SNCG (breast cancer-specific protein 1) Antibody |
|
BF0110-50ul |
Affinity Biosciences |
50ul |
EUR 150 |
|
Description: WB,IHC,ELISA |
) SNCG Antibody (breast cancer-specific protein 1) |
|
E10-20084 |
EnoGene |
100μg/100μl |
EUR 225 |
|
Description: Available in various conjugation types. |
SNCG Antibody (breast cancer-specific protein 1) |
|
MBS850341-01mg |
MyBiosource |
0.1mg |
EUR 305 |
SNCG Antibody (breast cancer-specific protein 1) |
|
MBS850341-01mLAF405L |
MyBiosource |
0.1mL(AF405L) |
EUR 565 |
SNCG Antibody (breast cancer-specific protein 1) |
|
MBS850341-01mLAF405S |
MyBiosource |
0.1mL(AF405S) |
EUR 565 |
SNCG Antibody (breast cancer-specific protein 1) |
|
MBS850341-01mLAF610 |
MyBiosource |
0.1mL(AF610) |
EUR 565 |
SNCG Antibody (breast cancer-specific protein 1) |
|
MBS850341-01mLAF635 |
MyBiosource |
0.1mL(AF635) |
EUR 565 |
 Antibody) Breast Cancer-Specific Gene 1 Protein (SNCG) Antibody |
|
abx011543-100g |
Abbexa |
100 µg |
Ask for price |
Breast Cancer-Specific Gene 1 Protein (SNCG) Antibody |
|
abx011543-100ul |
Abbexa |
100 ul |
EUR 493.2 |
|
|
Breast Cancer-Specific Gene 1 Protein (SNCG) Antibody |
|
abx011543-10g |
Abbexa |
10 µg |
EUR 362.5 |
Breast Cancer-Specific Gene 1 Protein (SNCG) Antibody |
|
abx011543-200g |
Abbexa |
200 µg |
Ask for price |
 Human colon cancer-specific antigen-4,CCSA-4 ELISA kit |
|
201-12-1665 |
Shanghai Sunred Biological Technology |
96 tests |
EUR 528 |
|
|
|
Description: A quantitative ELISA kit for measuring Human in samples from biological fluids. |
 Human colon cancer-specific antigen-2,CCSA-2 ELISA kit |
|
201-12-1681 |
Shanghai Sunred Biological Technology |
96 tests |
EUR 528 |
|
|
|
Description: A quantitative ELISA kit for measuring Human in samples from biological fluids. |
 Human colon cancer-specific antigen-3,CCSA-3 ELISA kit |
|
201-12-1721 |
Shanghai Sunred Biological Technology |
96 tests |
EUR 528 |
|
|
|
Description: A quantitative ELISA kit for measuring Human in samples from biological fluids. |
 Human colon cancer-specific antigen-2, CCSA-2 ELISA kit |
|
CSB-E11291h-24T |
Cusabio |
1 plate of 24 wells |
EUR 198 |
|
|
|
Description: Quantitativesandwich ELISA kit for measuring Human colon cancer-specific antigen-2, CCSA-2 in samples from serum, plasma, cell culture supernates, tissue homogenates. A new trial version of the kit, which allows you to test the kit in your application at a reasonable price. |
Human colon cancer-specific antigen-2,CCSA-2 ELISA kit |
|
CSB-E11291h-48T |
Cusabio |
48T |
EUR 338.81 |
|
|
|
Description: Homo sapiens (Human) |
Human colon cancer-specific antigen-2, CCSA-2 ELISA kit |
|
1-CSB-E11291h |
Cusabio |
-
Ask for price
-
Ask for price
-
Ask for price
|
- 1 plate of 96 wells
- 5 plates of 96 wells each
- 10 plates of 96 wells each
|
|
|
|
Description: Quantitativesandwich ELISA kit for measuring Human colon cancer-specific antigen-2, CCSA-2 in samples from serum, plasma, cell culture supernates, tissue homogenates. Now available in a cost efficient pack of 5 plates of 96 wells each, conveniently packed along with the other reagents in 5 separate kits. |
Human colon cancer-specific antigen-2,CCSA-2 ELISA kit |
|
CSB-E11291h-96T |
Cusabio |
96T |
EUR 521.25 |
|
|
|
Description: Homo sapiens (Human) |
 ELISA Kit) Human Colon cancer-specific antigen-2 (CCSA-2) ELISA Kit |
|
AE63011HU-48T |
Abebio |
48T |
EUR 325 |
|
|
|
Description: Human (Homo sapiens) |
Human Colon cancer-specific antigen-2 (CCSA-2) ELISA Kit |
|
AE63011HU-48Tests |
Abebio |
48 Tests |
EUR 325 |
|
|
|
Description: Human (Homo sapiens) |
Human Colon cancer-specific antigen-2 (CCSA-2) ELISA Kit |
|
AE63011HU-96T |
Abebio |
96T |
EUR 610 |
|
|
|
Description: Human (Homo sapiens) |
Human Colon cancer-specific antigen-2 (CCSA-2) ELISA Kit |
|
AE63011HU-96Tests |
Abebio |
96 Tests |
EUR 610 |
|
|
|
Description: Human (Homo sapiens) |
 ELISA Kit) Human Colon cancer-specific antigen-4 (CCSA-4) ELISA Kit |
|
AE63012HU-48T |
Abebio |
48T |
EUR 325 |
|
|
|
Description: Human (Homo sapiens) |
Human Colon cancer-specific antigen-4 (CCSA-4) ELISA Kit |
|
AE63012HU-48Tests |
Abebio |
48 Tests |
EUR 325 |
|
|
|
Description: Human (Homo sapiens) |
Human Colon cancer-specific antigen-4 (CCSA-4) ELISA Kit |
|
AE63012HU-96T |
Abebio |
96T |
EUR 610 |
|
|
|
Description: Human (Homo sapiens) |
Human Colon cancer-specific antigen-4 (CCSA-4) ELISA Kit |
|
AE63012HU-96Tests |
Abebio |
96 Tests |
EUR 610 |
|
|
|
Description: Human (Homo sapiens) |
ELISA Kit) Human colon cancer-specific antigen-4(CCSA-4)ELISA Kit |
|
GA-E1681HM-48T |
GenAsia Biotech |
48T |
EUR 346.8 |
Human colon cancer-specific antigen-4(CCSA-4)ELISA Kit |
|
GA-E1681HM-48Tests |
GenAsia Biotech |
48 Tests |
Ask for price |
Human colon cancer-specific antigen-4(CCSA-4)ELISA Kit |
|
GA-E1681HM-96T |
GenAsia Biotech |
96T |
EUR 559.2 |
Human colon cancer-specific antigen-4(CCSA-4)ELISA Kit |
|
GA-E1681HM-96Tests |
GenAsia Biotech |
96 Tests |
EUR 388 |
ELISA Kit) Human colon cancer-specific antigen-2(CCSA-2)ELISA Kit |
|
GA-E1697HM-48T |
GenAsia Biotech |
48T |
EUR 346.8 |
Human colon cancer-specific antigen-2(CCSA-2)ELISA Kit |
|
GA-E1697HM-48Tests |
GenAsia Biotech |
48 Tests |
Ask for price |
Human colon cancer-specific antigen-2(CCSA-2)ELISA Kit |
|
GA-E1697HM-96T |
GenAsia Biotech |
96T |
EUR 559.2 |
Human colon cancer-specific antigen-2(CCSA-2)ELISA Kit |
|
GA-E1697HM-96Tests |
GenAsia Biotech |
96 Tests |
EUR 388 |
ELISA Kit) Human colon cancer-specific antigen-3(CCSA-3)ELISA Kit |
|
GA-E1737HM-48T |
GenAsia Biotech |
48T |
EUR 346.8 |
Human colon cancer-specific antigen-3(CCSA-3)ELISA Kit |
|
GA-E1737HM-48Tests |
GenAsia Biotech |
48 Tests |
Ask for price |
Human colon cancer-specific antigen-3(CCSA-3)ELISA Kit |
|
GA-E1737HM-96T |
GenAsia Biotech |
96T |
EUR 559.2 |
Human colon cancer-specific antigen-3(CCSA-3)ELISA Kit |
|
GA-E1737HM-96Tests |
GenAsia Biotech |
96 Tests |
EUR 388 |
 Elisa Kit) Human colon cancer-specific antigen-2(CCSA-2) Elisa Kit |
|
EK700429 |
AFG Bioscience LLC |
96 Wells |
EUR 0.41 |
Human Colon cancer-specific antigen-2 (CCSA-2) ELISA Kit |
|
EK12062 |
SAB |
96Т |
EUR 799 |
|
|
Human Colon cancer-specific antigen-4 (CCSA-4) ELISA Kit |
|
EK12063 |
SAB |
96Т |
EUR 799 |
|
|
Human colon cancer-specific antigen-2,CCSA-2 ELISA kit |
|
EKC33236-48T |
Biomatik Corporation |
48T |
EUR 535.99 |
Human colon cancer-specific antigen-2,CCSA-2 ELISA kit |
|
EKC33236-5x96T |
Biomatik Corporation |
5x96T |
EUR 3637.08 |
Human colon cancer-specific antigen-2,CCSA-2 ELISA kit |
|
EKC33236-96T |
Biomatik Corporation |
96T |
EUR 765.7 |
 Human colon cancer-specific antigen-4,CCSA-4 ELISA KIT |
|
JOT-EK1664Hu |
Jotbody |
96 wells |
Ask for price |
|
Description: Human |
 Human colon cancer-specific antigen-2,CCSA-2 ELISA KIT |
|
JOT-EK1680Hu |
Jotbody |
96 wells |
Ask for price |
|
Description: Human |
 Human colon cancer-specific antigen-3,CCSA-3 ELISA KIT |
|
JOT-EK1720Hu |
Jotbody |
96 wells |
Ask for price |
|
Description: Human |
Human Colon cancer-specific antigen-2 (CCSA-2) ELISA Kit |
|
KTE62591-48T |
Abbkine |
48T |
EUR 339 |
|
|
|
Description: This Human Colon cancer-specific antigen-2 (CCSA-2) ELISA Kit employs a two-site sandwich ELISA to quantitate CCSA-2. |
Human Colon cancer-specific antigen-2 (CCSA-2) ELISA Kit |
|
KTE62591-96T |
Abbkine |
96T |
EUR 589 |
|
|
|
Description: This Human Colon cancer-specific antigen-2 (CCSA-2) ELISA Kit employs a two-site sandwich ELISA to quantitate CCSA-2. |
Human Colon cancer-specific antigen-2 (CCSA-2) ELISA Kit |
|
KTE62591-96T5 |
Abbkine |
96 T×5 |
EUR 2629 |
|
Description: This Human Colon cancer-specific antigen-2 (CCSA-2) ELISA Kit employs a two-site sandwich ELISA to quantitate CCSA-2. |
Human Colon cancer-specific antigen-2 (CCSA-2) ELISA Kit |
|
KTE62591-96T50 |
Abbkine |
96 T×50 |
EUR 24569 |
|
Description: This Human Colon cancer-specific antigen-2 (CCSA-2) ELISA Kit employs a two-site sandwich ELISA to quantitate CCSA-2. |
 (1H10D2)) anti-SNCG (breast cancer-specific protein 1) (1H10D2) |
|
LF-MA30069 |
Abfrontier |
100 ul |
EUR 534 |
|
Description: Mouse Monoclonal to SNCG (breast cancer-specific protein 1) |
 Mouse mAb) Anti-SNCG (breast cancer-specific protein 1) Mouse mAb |
|
MBS475702-01mL |
MyBiosource |
0.1mL |
EUR 450 |
Anti-SNCG (breast cancer-specific protein 1) Mouse mAb |
|
MBS475702-5x01mL |
MyBiosource |
5x0.1mL |
EUR 1540 |
Human Colon cancer-specific antigen-2 (CCSA-2) ELISA Kit |
|
MBS285082-10x96StripWells |
MyBiosource |
10x96-Strip-Wells |
EUR 6255 |
Human Colon cancer-specific antigen-2 (CCSA-2) ELISA Kit |
|
MBS285082-48StripWells |
MyBiosource |
48-Strip-Wells |
EUR 445 |
Human Colon cancer-specific antigen-2 (CCSA-2) ELISA Kit |
|
MBS285082-5x96StripWells |
MyBiosource |
5x96-Strip-Wells |
EUR 3290 |
Human Colon cancer-specific antigen-2 (CCSA-2) ELISA Kit |
|
MBS285082-96StripWells |
MyBiosource |
96-Strip-Wells |
EUR 730 |
 Human colon cancer-specific antigen-4, CCSA-4 ELISA Kit |
|
MBS164035-10x96StripWells |
MyBiosource |
10x96-Strip-Wells |
EUR 3460 |
Human colon cancer-specific antigen-4, CCSA-4 ELISA Kit |
|
MBS164035-48StripWells |
MyBiosource |
48-Strip-Wells |
EUR 285 |
Human colon cancer-specific antigen-4, CCSA-4 ELISA Kit |
|
MBS164035-5x96StripWells |
MyBiosource |
5x96-Strip-Wells |
EUR 1750 |
Human colon cancer-specific antigen-4, CCSA-4 ELISA Kit |
|
MBS164035-96StripWells |
MyBiosource |
96-Strip-Wells |
EUR 425 |
 Human colon cancer-specific antigen-3, CCSA-3 ELISA Kit |
|
MBS164066-10x96StripWells |
MyBiosource |
10x96-Strip-Wells |
EUR 3460 |
Human colon cancer-specific antigen-3, CCSA-3 ELISA Kit |
|
MBS164066-48StripWells |
MyBiosource |
48-Strip-Wells |
EUR 285 |
Human colon cancer-specific antigen-3, CCSA-3 ELISA Kit |
|
MBS164066-5x96StripWells |
MyBiosource |
5x96-Strip-Wells |
EUR 1750 |
Human colon cancer-specific antigen-3, CCSA-3 ELISA Kit |
|
MBS164066-96StripWells |
MyBiosource |
96-Strip-Wells |
EUR 425 |
 Human colon cancer-specific antigen-2, CCSA-2 ELISA Kit |
|
MBS161091-10x96StripWells |
MyBiosource |
10x96-Strip-Wells |
EUR 3460 |
Human colon cancer-specific antigen-2, CCSA-2 ELISA Kit |
|
MBS161091-48StripWells |
MyBiosource |
48-Strip-Wells |
EUR 285 |
Human colon cancer-specific antigen-2, CCSA-2 ELISA Kit |
|
MBS161091-5x96StripWells |
MyBiosource |
5x96-Strip-Wells |
EUR 1750 |
Human colon cancer-specific antigen-2, CCSA-2 ELISA Kit |
|
MBS161091-96StripWells |
MyBiosource |
96-Strip-Wells |
EUR 425 |
Human colon cancer-specific antigen-2, CCSA-2 ELISA Kit |
|
MBS702744-10x96StripWells |
MyBiosource |
10x96-Strip-Wells |
EUR 5575 |
Human colon cancer-specific antigen-2, CCSA-2 ELISA Kit |
|
MBS702744-24StripWellsLIMIT1 |
MyBiosource |
24-Strip-Wells(LIMIT1) |
EUR 275 |
Human colon cancer-specific antigen-2, CCSA-2 ELISA Kit |
|
MBS702744-48StripWells |
MyBiosource |
48-Strip-Wells |
EUR 545 |
Human colon cancer-specific antigen-2, CCSA-2 ELISA Kit |
|
MBS702744-5x96StripWells |
MyBiosource |
5x96-Strip-Wells |
EUR 2920 |
Human colon cancer-specific antigen-2, CCSA-2 ELISA Kit |
|
MBS702744-96StripWells |
MyBiosource |
96-Strip-Wells |
EUR 765 |
 Human colon cancer-specific antigen-2,CCSA-2 ELISA Kit |
|
SL0493Hu |
Sunlong |
96 Tests |
EUR 468 |
|
|
 Human colon cancer-specific antigen-3,CCSA-3 ELISA Kit |
|
SL0494Hu |
Sunlong |
96 Tests |
EUR 468 |
|
|
 Human colon cancer-specific antigen-4,CCSA-4 ELISA Kit |
|
SL0495Hu |
Sunlong |
96 Tests |
EUR 468 |
|
|
Human colon cancer-specific antigen-3,CCSA-3 ELISA kit |
|
YLA0511HU-48T |
Shanghai YL Biotech |
48T |
Ask for price |
A complete of 608 differentially expressed genes have been recognized between excessive and low TMB teams, KEGG base excision restore and DNA replication pathways have been enriched in excessive TMB group. Infiltration ranges of M0 macrophages have been greater and dendritic resting cells have been decrease in excessive TMB group. Lastly, a nomogram mannequin integrating TMB and immune infiltration was established.
